EWTX
HEALTHCAREEdgewise Therapeutics Inc
AI Insight
What's Moving EWTX Today?
No stock-specific AI insight has been generated for EWTX yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring EWTX
52-Week Range
$12.15$40.77
$38.48
Fundamentals
Market Cap$4.0B
P/E Ratio—
EPS$-1.66
Dividend Yield—
Dividend / Share—
ROE-38.1%
Profit Margin—
Debt / Equity—
Trading
Volume585K
Avg Volume (10D)—
Shares Outstanding107.6M
EWTX News
22 articles- Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC SaysYahoo Finance·Jun 17, 2026
- Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?Yahoo Finance·Jun 16, 2026
- Edgewise Therapeutics Reports Improvements In Heart Drug TrialYahoo Finance·Jun 16, 2026
- SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fallYahoo Finance·Jun 16, 2026
- Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)Yahoo Finance·Jun 16, 2026
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesYahoo Finance·Jun 3, 2026
- Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price MoveYahoo Finance·Jun 2, 2026
- Edgewise Therapeutics Stock Hits Record High on $2.65B Servier DealYahoo Finance·Jun 2, 2026
- Servier to acquire Edgewise’s muscular dystrophy business for $2.65bnPharmaceutical-technology·Jun 2, 2026
- How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key OverhangYahoo Finance·Jun 1, 2026
- EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy BusinessStocktwits·Jun 1, 2026
- Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular PipelineYahoo Finance·Jun 1, 2026
- Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy BusinessYahoo Finance·Jun 1, 2026
- Servier buys into muscular dystrophy with potentially $2.7B dealBiopharmadive·Jun 1, 2026
- Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder DrugMSN·May 30, 2026
- Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% RallyMotley Fool·May 18, 2026
- Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterMotley Fool·May 17, 2026
- Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyMotley Fool·May 17, 2026
- Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million MoreMotley Fool·May 17, 2026
- What to Know About This Fund’s $50 Million Exit From Ascendis PharmaMotley Fool·May 14, 2026
- This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPOMotley Fool·May 14, 2026
- Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular IndicationsPR Newswire·May 7, 2026
All 22 articles loaded
Price Data
Open$36.31
Previous Close$36.50
Day High$39.34
Day Low$36.03
52 Week High$40.77
52 Week Low$12.15
52-Week Range
$12.15$40.77
$38.48
Fundamentals
Market Cap$4.0B
P/E Ratio—
EPS$-1.66
Dividend Yield—
Dividend / Share—
ROE-38.1%
Profit Margin—
Debt / Equity—
Trading
Volume585K
Avg Volume (10D)—
Shares Outstanding107.6M
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—